Genetic Modification of T Cells

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 1 SUPPL, 2011, Pages

  Bonini, Chiara ^a   Brenner, Malcolm K ^b   Heslop, Helen E ^b   Morgan, Richard A ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Gene transfer; Suicide genes; T lymphocytes

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DNA MODIFICATION; DRUG MEGADOSE; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HUMAN; KIDNEY CANCER; LYMPHOCYTE FUNCTION; LYMPHOMA; MELANOMA; NEUROBLASTOMA; OVARY CANCER; SUICIDE GENE; T LYMPHOCYTE; VIRUS INFECTION; WHOLE BODY RADIATION;

EID: 78650636797     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.09.019     Document Type: Article

References (47)

1. Kolb H.J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008, 112:4371-4383.
2. Leen A.M., Myers G.D., Sili U., et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006, 12:1160-1166.
3. O'Reilly R.J., Doubrovina E., Trivedi D., et al. Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants. Immunol Res 2007, 38:237-250.
4. Peggs K.S., Verfuerth S., Pizzey A., et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet 2003, 362:1375-1377.
5. Heslop H.E., Slobod K.S., Pule M.A., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115:925-935.
6. Warren E.H., Fujii N., Akatsuka Y., et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010, 115:3869-3878.
7. Bollard C.M., Gottschalk S., Leen A.M., et al. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood 2007, 110:2838-2845.
8. Dudley M.E., Wunderlich J.R., Yang J.C., et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005, 23:2346-2357.
9. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5:263-274.
10. Stewart T.J., Abrams S.I. How tumours escape mass destruction. Oncogene 2008, 27:5894-5903.
11. Ciceri F., Bonini C., Marktel S., et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007, 109:4698-4707.
12. Berger C., Jensen M.C., Lansdorp P.M., et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008, 118:294-305.
13. Hinrichs C.S., Borman Z.A., Cassard L., et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009, 106:17469-17474.
14. Kaneko S., Mastaglio S., Bondanza A., et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 2009, 113:1006-1015.
15. Hoyos V., Savoldo B., Quintarelli C., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.
16. Mills C.D., North R.J. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med 1983, 157:1448-1460.
17. Wang L.X., Shu S., Plautz G.E. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells. Cancer Res 2005, 65:9547-9554.
18. Overwijk W.W., Theoret M.R., Finkelstein S.E., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198:569-580.
19. Muranski P., Boni A., Wrzesinski C., et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat Clin Pract Oncol 2006, 3:668-681.
20. Laport G.G., Levine B.L., Stadtmauer E.A., et al. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin's lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 2003, 102:2004-2013.
21. Dudley M.E., Wunderlich J.R., Robbins P.F., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
22. Morgan R.A., Dudley M.E., Rosenberg S.A. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 2010, 16:336-341.
23. Morgan R.A., Dudley M.E., Wunderlich J.R., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
24. Johnson L.A., Morgan R.A., Dudley M.E., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
25. Kershaw M.H., Westwood J.A., Parker L.L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006, 12:6106-6115.
26. Jensen M.C., Popplewell L., Cooper L.J., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010, 16:1245-1256.
27. Till B.G., Jensen M.C., Wang J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
28. Lamers C.H., Langeveld S.C., Groot-van Ruijven C.M., et al. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo. Cancer Immunol Immunother 2007, 56:1875-1883.
29. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833.
30. Zhao Y., Wang Q.J., Yang S., et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009, 183:5563-5574.
31. Morgan R.A., Yang J.C., Kitano M., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010, 18:843-851.
32. Brentjens R., Yeh R., Bernal Y., Riviere I., Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010, 18:666-668.
33. Heslop H.E. Safer CARS. Mol Ther 2010, 18:661-662.
34. Pule M.A., Savoldo B., Myers G.D., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008, 14:1264-1270.
35. Foster A.E., Dotti G., Lu A., et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008, 31:500-505.
36. Bollard C.M., Rossig C., Calonge M.J., et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002, 99:3179-3187.
37. Vera J.F., Hoyos V., Savoldo B., et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009, 17:880-888.
38. Heemskerk B., Liu K., Dudley M.E., et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 2008, 19:496-510.
39. Brewin J., Mancao C., Straathof K., et al. Generation of EBV-specific cytotoxic T-cells that are resistant to calcineurin inhibitors for the treatment of post-transplant lymphoproliferative disease. Blood 2009, 114:4792-4803.
40. De Angelis B., Dotti G., Quintarelli C., et al. Generation of Epstein-Barr-virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009, 114:4784-4791.
41. Bonini C., Bondanza A., Perna S.K., et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther 2007, 15:1248-1252.
42. Ciceri F., Bonini C., Stanghellini M.T., et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 2009, 10:489-500.
43. Traversari C., Marktel S., Magnani Z., et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007, 109:4708-4715.
44. Tey S.K., Dotti G., Rooney C.M., Heslop H.E., Brenner M.K. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007, 13:913-924.
45. June C.H., Blazar B.R., Riley J.L. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol 2009, 9:704-716.
46. Vera J.F., Brenner L.J., Gerdemann U., et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010, 33:305-315.
47. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically-engineered to recognize CD19. Blood 2010, [Epub ahead of print].